What is a cytology (cell study) test, specifically a Pap (Papanicolaou) test, for cervical cancer screening in women?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 17, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

What is a Cytology Test?

A cytology test is a microscopic examination of cells collected from the body to detect abnormalities, and in the context of cervical cancer screening, it specifically refers to the Pap (Papanicolaou) test—a procedure that collects and examines cells from the cervix to identify precancerous changes and early cancer. 1

Purpose and Clinical Significance

The primary goal of cervical cytology is the early detection, diagnosis, and treatment of cancer precursor lesions and invasive cancer before they progress to life-threatening disease. 1 This screening method has proven to be the most successful cancer prevention strategy in modern medicine, reducing cervical cancer incidence by 75% and mortality by 74% in the United States over 50 years. 1

How the Test Works

Cell Collection Methods

Cervical cytology involves collecting cells from the cervix using specialized instruments designed to sample the transformation zone (the area where most cervical cancers develop). 2 Two main collection techniques exist:

  • Conventional Pap smear: The sampling device is smeared directly onto a glass slide with immediate spray fixation, though this method is subject to air-drying artifact if fixation is delayed. 3

  • Liquid-based cytology (LBC): The sampling device is placed directly into liquid fixative, providing immediate fixation, eliminating air-drying artifact, and allowing for more even cell distribution. 4, 3 This is now the predominant method used in the United States. 1

Laboratory Analysis

The collected cells are examined under a microscope using the 2001 Bethesda System for reporting results. 1 The laboratory evaluates cellular characteristics to identify:

  • Normal cells (negative for intraepithelial lesion or malignancy)
  • Precancerous changes (low-grade or high-grade squamous intraepithelial lesions)
  • Invasive cancer cells 1

Clinical Advantages

The success of cervical cytology reflects several key factors:

  • Slow disease progression: The generally slow progression from precancerous lesions to invasive cancer provides ample opportunities for early detection. 1

  • Detectable abnormalities: The ability to identify cytologic abnormalities before invasive disease appears. 1

  • Effective treatment: Availability of minimally morbid therapy for premalignant disease. 1

  • Repeat testing strategy: Frequent repetition of the test increases detection rates over time. 1

Modern Screening Approach

Current guidelines recommend primary HPV testing every 5 years starting at age 25 as the preferred screening strategy, though cytology alone every 3 years or cotesting (cytology plus HPV testing) every 5 years remain acceptable alternatives during the transition period. 1 The combination of HPV testing with cytology improves screening efficacy compared to cytology alone and allows for safer screening with increased intervals. 1

Test Limitations

Despite its success, cervical cytology has important limitations:

  • Suboptimal single-test sensitivity: The imperfect sensitivity is estimated to be responsible for 30% of all cervical cancers. 1

  • Limited reproducibility: Results can vary between readings. 1

  • Equivocal results: Many results fall into uncertain categories requiring additional testing. 1

  • Higher sensitivity but lower specificity with LBC: Liquid-based cytology detects more abnormalities but also generates more false positives compared to conventional methods. 3

Critical Pitfall

Half of all women who develop cervical cancer in the United States have never been screened, and an additional 10% have not been screened within 5 years of diagnosis. 1 This underscores that the primary failure of cervical cancer prevention is not the test itself, but rather failure to reach at-risk populations who do not participate in regular screening programs.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

HPV Primary Screening Test Procedure

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Cervical Cancer Screening Methods

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Cervical Cancer Screening with Liquid-Based Cytology

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Related Questions

What is the recommended cervical cancer screening schedule for a [AGE]-year-old woman with a last normal Pap (Papanicolau) smear in [YEAR]?
What are the next steps for a patient with a Pap smear showing cervical dysplasia?
Can a Pap (Papanicolau) smear be performed on someone without a cervix?
What is the recommended follow-up for a patient with cytopathologic changes suggestive of herpes (Human Papillomavirus) on Pap (Papanicolaou) cytology?
What is the most appropriate next step in management for a sexually active woman with vaginal discharge and an abnormal Pap (Papanicolaou) smear result?
Are there interactions between linezolid (monoamine oxidase inhibitor) and tramadol in patients, particularly those with impaired renal (kidney) function or hepatic (liver) impairment?
What is the best course of treatment for a patient presenting with hypercalcemia and joint pain?
What is the diagnostic approach for an older patient with potential underlying health conditions and symptoms such as fever, cough, shortness of breath, and chest pain to identify the type of pneumonia?
For an 18-year-old patient with a history of otitis media, presenting with throat ache, tonsillitis and low-grade fever, which IV antibiotic is more appropriate, ceftriaxone 1 gram or Cefazolin 1 gram?
What is the appropriate management for a pregnant patient with a positive pregnancy test presenting with clotting and abdominal pain, potentially indicating an ectopic pregnancy or placental abruption?
What happens if a patient with type 2 diabetes, taking metformin, vildagliptin, and regular insulin, receives 20 units of glargine (insulin glargine) at 4 pm and 20 units at 11 pm?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.